Welcome to our dedicated page for Metagenomi Therapeutics SEC filings (Ticker: MGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Metagenomi Therapeutics, Inc. (Nasdaq: MGX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public biotechnology issuer focused on in vivo genome editing and precision genetic medicines. These filings offer detailed information on financial performance, pipeline progress, and key corporate events related to its proprietary gene editing toolbox and programs such as MGX-001 for hemophilia A.
Metagenomi, Inc. files current reports on Form 8-K to announce material events, including quarterly financial results, business updates, and new preclinical data. For example, Form 8-K filings reference press releases that discuss non-human primate data for MGX-001, strategic pipeline prioritization, and corporate presentations. These 8-Ks often furnish exhibits containing full press releases and investor slide decks, which can provide additional scientific and strategic context.
Investors can also review quarterly reports on Form 10-Q and other periodic filings, which the company notes in its press releases, for more comprehensive discussions of research and development activities, collaboration revenue, operating expenses, and risk factors. As an emerging growth company, Metagenomi discloses its status and related accounting elections within these documents.
On Stock Titan, MGX filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize lengthy documents such as 10-Qs and 10-Ks, highlight key sections, and clarify technical language. Users can quickly identify items related to in vivo genome editing programs, collaboration agreements, capital allocation, and organizational changes. In addition, Form 4 and other insider transaction reports, when filed, can be reviewed to monitor trading activity by directors and officers.
This page is a central resource for analyzing Metagenomi Therapeutics’ official disclosures, from financial results and pipeline data to governance updates, supporting deeper research into the MGX investment and its genome editing platform.
Metagenomi Therapeutics director and officer Jian Irish reported equity awards and updated holdings. She received a stock option covering 276,000 shares of common stock at an exercise price of $1.34 per share, expiring on March 31, 2036, with 25% vesting on April 1, 2027 and the rest in 36 monthly installments. She also received 46,000 restricted stock units, 25% of which vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments. Following these awards, she holds 379,770 shares of common stock directly, and additional shares are held indirectly by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish and the Jian Irish 2023 Irrevocable Trust, where she disclaims beneficial ownership except to the extent of her pecuniary interest.
Wein Matthew reported acquisition or exercise transactions in this Form 4 filing.
Metagenomi Therapeutics officer Matthew Wein received new equity awards. On April 1, 2026, he was granted options to buy 68,000 shares of common stock at $1.34 per share, expiring on March 31, 2036. The option vests 25% on April 1, 2027, with the rest in 36 equal monthly installments, contingent on continued service. He was also granted 11,000 restricted stock units that begin vesting 25% on June 5, 2027, then in 12 equal quarterly installments. Following these compensation-related grants, his direct common stock holdings total 125,549 shares.
Metagenomi Therapeutics Chief Financial Officer Pamela Wapnick reported new equity awards. She received a grant of 144,000 stock options with an exercise price of $1.34 per share, expiring on March 31, 2036. These options relate to 144,000 shares of common stock.
She was also granted 24,000 shares of common stock in the form of restricted stock units. Twenty-five percent of the RSUs vest on June 5, 2027, with the rest vesting in 12 equal quarterly installments. Her directly owned common stock holdings total 211,375 shares after these grants. The option award vests 25% on April 1, 2027, with the remainder vesting in 36 equal monthly installments.
Metagenomi Therapeutics, Inc. Chief Financial Officer Pamela Wapnick reported an automatic sale of common stock related to tax withholding. On this transaction date, 1,581 shares of common stock were sold at $1.60 per share. According to the footnote, the shares were automatically sold to satisfy her tax withholding obligations upon the vesting of restricted stock units granted on April 1, 2024, and the transaction did not represent a voluntary trade. After this sale, Wapnick beneficially owned 187,375 shares of common stock directly.
Metagenomi Therapeutics, Inc. officer Matthew Wein reported an automatic sale of common stock related to equity compensation. On March 5, 2026, 482 shares of common stock were sold at $1.60 per share to satisfy tax withholding obligations upon the vesting of restricted stock units granted on April 1, 2024 and April 1, 2025. The filing notes this was not a volitional trade by the reporting person. Following this transaction, Wein beneficially owned 114,549 shares of Metagenomi Therapeutics common stock.
Metagenomi Therapeutics Chief Executive Officer Jian Irish reported both a tax-related share sale and large gifts of stock. On December 5, 2025, she transferred 114,231 shares to the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish and 114,231 shares to the Jian Irish 2023 Irrevocable Trust as bona fide gifts for no consideration. These trusts now hold shares for which she disclaims beneficial ownership except for any pecuniary interest. On March 5, 2026, 1,607 shares of common stock were automatically sold at $1.60 per share to satisfy tax withholding obligations from restricted stock units that vested on April 1, 2024, leaving her with 333,770 shares held directly.
Metagenomi Therapeutics, Inc. is an in vivo genome editing company developing curative genetic medicines using a large metagenomics-derived toolbox of novel nucleases, base editors and integration systems. Its lead wholly owned program, MGX-001 for hemophilia A, inserts a Factor VIII gene into a liver “safe harbor” site to achieve durable expression.
In non-human primates, MGX-001 generated Factor VIII activity generally within the 50%–150% normal range with dose-dependent responses and an encouraging safety profile, and has also shown no detectable off-target editing in orthogonal assays. A pre-IND meeting was completed and the company plans an IND submission in the fourth quarter of 2026, followed by clinical trials, subject to regulatory clearance.
In late 2025 Metagenomi reprioritized its pipeline around MGX-001 and later-stage preclinical programs, reduced its workforce by 25% and extended its projected cash runway into the fourth quarter of 2027. The company rebranded as Metagenomi Therapeutics, Inc. and continues to expand applications of its MGX-001 integration system to other secreted protein deficiencies, while advancing a multi-target cardiometabolic collaboration with Ionis and leveraging a licensed lipid nanoparticle delivery platform.
Metagenomi Therapeutics, Inc. reported full year 2025 results alongside key pipeline updates. The company ended December 31, 2025 with $160.8 million in cash, cash equivalents and marketable securities and expects this to fund operations through the fourth quarter of 2027.
Collaboration revenue was $25.2 million for 2025, while research and development expenses were $94.4 million and general and administrative expenses were $26.8 million. Net loss was $87.9 million, or $2.36 per basic and diluted share, on 37.3 million weighted average shares outstanding.
Operationally, the company completed a pre-IND meeting for its lead hemophilia A program MGX-001 after preclinical data in non-human primates showed curative FVIII activity, and it remains on track for a global regulatory submission, including an IND in the fourth quarter of 2026. It also reported in vivo proof-of-concept for Antithrombin (AT-III) Deficiency, advanced cardiometabolic collaborations with Ionis around APOC3, and completed a corporate name change to Metagenomi Therapeutics, Inc.
Metagenomi, Inc. has changed its corporate name to Metagenomi Therapeutics, Inc., effective 12:01 a.m. Pacific Time on January 12, 2026, through a certificate of amendment to its charter approved by the board under Delaware law. The change does not affect stockholder rights.
The board also amended and restated the company’s bylaws solely to reflect the new name, with no other changes. The company’s common stock will continue to trade on the Nasdaq Global Select Market under the symbol MGX, and the CUSIP number for the common stock will remain the same. A press release and a January 2026 corporate presentation related to the name change and business updates were furnished as exhibits.
Metagenomi, Inc. (MGX) reported Q3 2025 results. Collaboration revenue was $8.7 million, down from $11.5 million a year ago, while operating expenses declined to $31.5 million from $33.9 million. Net loss was $20.4 million versus $18.8 million last year, or $0.55 per share.
Cash and cash equivalents were $32.8 million and available-for-sale marketable securities were $151.3 million as of September 30, 2025, supporting management’s view that liquidity is sufficient for at least the next 12 months. Deferred revenue totaled $14.8 million, reflecting ongoing recognition under the Ionis collaboration.
The company terminated the Affini‑T agreement following Affini‑T’s assignment for the benefit of creditors and marked its Affini‑T investment to zero. Metagenomi also signed a non‑exclusive LNP license with Acuitas, recording a $3.0 million upfront licensing fee in research and development expense. Under the Ionis agreement, the company recognized $8.5 million of collaboration revenue in Q3 and reported $20.0 million remaining performance obligations to be recognized over future periods. Shares outstanding were 37,546,751 as of September 30, 2025.